Repligen Corp. 10-Q Summary: Quarter Ended December 31, 2007
Business Context and Reporting Period
This is an unaudited quarterly report (Form 10-Q) for Repligen Corporation, a biopharmaceutical company focused on novel therapeutics for central nervous system diseases and commercial products including Protein A and SecreFlo. The reporting period covers the three and nine months ended December 31, 2007.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2007 | Nine Months Ended Dec 31, 2007 |
|---|---|---|
| Total Revenue | $4.66 million | $16.00 million |
| Net Income (Loss) | $(0.24) million | $40.30 million |
| Operating Cash Flow | N/A | $38.74 million |
| Cash and Marketable Securities | $61.34 million (as of Dec 31, 2007) | |
| Total Liabilities | $3.34 million | |
| Stockholders' Equity | $67.12 million |
Note: The nine-month net income includes a significant non-recurring gain from litigation settlement.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 20.1% for the quarter and 54.2% for the nine-month period compared to the prior year. Product revenue (Protein A) rose 28.1% quarterly and 66.1% year-to-date, driven by an 82% increase in volume despite a 7% decrease in average selling price.
- Profitability Shift: The company reported a net loss of $0.24 million for the quarter but a net income of $40.30 million for the nine-month period. This dramatic swing is primarily due to a $40.17 million net gain from a litigation settlement with ImClone Systems recorded in the nine-month period.
- Operating Expenses: Excluding the litigation gain, operating expenses increased 38.5% year-to-date. Cost of product revenue rose 79% due to higher material and personnel costs supporting increased sales. Selling, general, and administrative (SG&A) expenses increased 43%, largely due to litigation costs associated with a patent infringement lawsuit against Bristol-Myers Squibb.
- Liquidity: Cash and marketable securities increased from $22.63 million at March 31, 2007, to $61.34 million at December 31, 2007, fueled by the ImClone settlement proceeds.
Outlook, Risks, and Unusual Items
- Unusual Item (Litigation Settlement): On September 10, 2007, Repligen settled a patent infringement lawsuit with ImClone. The settlement resulted in $65 million gross proceeds, with $40.17 million net to Repligen after payments to MIT and legal fees. This is a non-recurring event.
- Ongoing Litigation: Repligen is engaged in patent infringement litigation against Bristol-Myers Squibb regarding the '941 patent. A trial is scheduled to commence in April 2008. The outcome is undeterminable, and significant legal expenses have been incurred.
- Product Supply: The last shipment of SecreFlo vials was received in July 2007. Inventory is expected to last through the second quarter of fiscal year 2009. Future revenue from this product is limited to existing inventory.
- Strategic Investments: The company entered into a license agreement with The Scripps Research Institute for technology related to Friedreich's Ataxia, incurring $300,000 in initial fees and issuing stock.
- Capital Resources: Management believes current cash and investment balances are adequate to meet needs absent acquisitions. However, future capital requirements depend on clinical trial success and R&D progress.
Investor Verification Checklist
- Verify the sustainability of Protein A revenue growth given the 7% decrease in average selling price.
- Assess the impact of the $40.17 million litigation gain on the company's reported profitability and tax position (effective tax rate was 2% due to NOLs).
- Monitor the status and potential costs of the ongoing patent litigation against Bristol-Myers Squibb.
- Confirm the timeline for SecreFlo inventory depletion and the lack of new supply agreements.
- Review the progress and funding requirements for the new Friedreich's Ataxia program with Scripps.